Structured learning of sum-of-submodular higher order energy functions

Submodular functions can be exactly minimized in polynomial time, and the special case that graph cuts solve with max flow \cite{KZ:PAMI04} has had significant impact in computer vision \cite{BVZ:PAMI01,Kwatra:SIGGRAPH03,Rother:GrabCut04}. In this paper we address the important class of sum-of-submodular (SoS) functions \cite{Arora:ECCV12,Kolmogorov:DAM12}, which can be efficiently minimized via a variant of max flow called submodular flow \cite{Edmonds:ADM77}. SoS functions can naturally express higher order priors involving, e.g., local image patches; however, it is difficult to fully exploit their expressive power because they have so many parameters. Rather than trying to formulate existing higher order priors as an SoS function, we take a discriminative learning approach, effectively searching the space of SoS functions for a higher order prior that performs well on our training set. We adopt a structural SVM approach \cite{Joachims/etal/09a,Tsochantaridis/etal/04} and formulate the training problem in terms of quadratic programming; as a result we can efficiently search the space of SoS priors via an extended cutting-plane algorithm. We also show how the state-of-the-art max flow method for vision problems \cite{Goldberg:ESA11} can be modified to efficiently solve the submodular flow problem. Experimental comparisons are made against the OpenCV implementation of the GrabCut interactive segmentation technique \cite{Rother:GrabCut04}, which uses hand-tuned parameters instead of machine learning. On a standard dataset \cite{Gulshan:CVPR10} our method learns higher order priors with hundreds of parameter values, and produces significantly better segmentations. While our focus is on binary labeling problems, we show that our techniques can be naturally generalized to handle more than two labels

Structured learning of sum-of-submodular higher order energy functions

Submodular functions can be exactly minimized in polynomial time, and the special case that graph cuts solve with max flow [18] has had significant impact in computer vision [5, 20, 27]. In this paper we address the important class of sum-of-submodular (SoS) functions [2, 17], which can be efficiently minimized via a variant of max flow called submodular flow [6]. SoS functions can naturally express higher order priors involving, e.g., local image patches; however, it is difficult to fully exploit their expressive power because they have so many parameters. Rather than trying to formulate existing higher order priors as an SoS function, we take a discriminative learning approach, effectively searching the space of SoS functions for a higher order prior that performs well on our training set. We adopt a structural SVM approach [14, 33] and formulate the training problem in terms of quadratic programming; as a result we can efficiently search the space of SoS priors via an extended cutting-plane algorithm. We also show how the state-of-the-art max flow method for vision problems [10] can be modified to efficiently solve the submodular flow problem. Experimental comparisons are made against the OpenCV implementation of the GrabCut interactive segmentation technique [27], which uses hand-tuned parameters instead of machine learning. On a standard dataset [11] our method learns higher order priors with hundreds of parameter values, and produces significantly better segmentations. While our focus is on binary labeling problems, we show that our techniques can be naturally generalized to handle more than two labels. 1

Pauci-immune glomerulonephritis in individuals with disease associated with levamisole-adulterated cocaine: a series of 4 cases.

Exposure to levamisole-adulterated cocaine can induce a distinct clinical syndrome characterized by retiform purpura and/or agranulocytosis accompanied by an unusual constellation of serologic abnormalities including antiphospholipid antibodies, lupus anticoagulants, and very high titers of antineutrophil cytoplasmic antibodies. Two recent case reports suggest that levamisole-adulterated cocaine may also lead to renal disease in the form of pauci-immune glomerulonephritis. To explore this possibility, we reviewed cases of pauci-immune glomerulonephritis between 2010 and 2012 at an inner city safety net hospital where the prevalence of levamisole in the cocaine supply is known to be high. We identified 3 female patients and 1 male patient who had biopsy-proven pauci-immune glomerulonephritis, used cocaine, and had serologic abnormalities characteristic of levamisole-induced autoimmunity. Each also had some other form of clinical disease known to be associated with levamisole, either neutropenia or cutaneous manifestations. One patient had diffuse alveolar hemorrhage. Three of the 4 patients were treated with short courses of prednisone and cyclophosphamide, 2 of whom experienced stable long-term improvement in their renal function despite ongoing cocaine use. The remaining 2 patients developed end-stage renal disease and became dialysis-dependent. This report supports emerging concern of more wide spread organ toxicity associated with the use of levamisole-adulterated cocaine

Multimodal active speaker detection and virtual cinematography for video conferencing

Active speaker detection (ASD) and virtual cinematography (VC) can significantly improve the remote user experience of a video conference by automatically panning, tilting and zooming of a video conferencing camera: users subjectively rate an expert video cinematographer's video significantly higher than unedited video. We describe a new automated ASD and VC that performs within 0.3 MOS of an expert cinematographer based on subjective ratings with a 1-5 scale. This system uses a 4K wide-FOV camera, a depth camera, and a microphone array; it extracts features from each modality and trains an ASD using an AdaBoost machine learning system that is very efficient and runs in real-time. A VC is similarly trained using machine learning to optimize the subjective quality of the overall experience. To avoid distracting the room participants and reduce switching latency the system has no moving parts -- the VC works by cropping and zooming the 4K wide-FOV video stream. The system was tuned and evaluated using extensive crowdsourcing techniques and evaluated on a dataset with N=100 meetings, each 2-5 minutes in length

Determination of resilience factors in individuals who tested COVID-19 positive

The main purpose of this study was to determine the protective factors that can aid people in their recovery or help maintain their well-being in the face of collective adversity, in this case, the COVID-19 pandemic, and to examine how these factors can be further strengthened. The study included 89 participants from 14 different cities in Turkey, ranging in age from 18 to 70, 46 of them men and 43 women. In light of the findings of the study, it can be said that psychosocial support and re-adaptation programmes are needed to ease the social-emotional burden of living through a pandemic on individuals (especially those who survived the virus) even after the COVID-19 pandemic ends

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Report of Dialysis-Induced Hypophosphatemia Leading to Reversible Encephalopathy Prevented by Adding Phosphorus to the Dialysate

Patients with advanced chronic kidney disease have an inability to excrete phosphorus normally leading to high serum concentrations of phosphorus. The hyperphosphatemia is even more pronounced in dialysis patients who often require large doses of phosphorus binders to combat the problem. Hemodialysis is able to remove fair amount of the extra phosphorus; however, the removal is often hampered by the fact that the phosphorus is removed only from the extracellular compartment and phosphorus is mainly intracellular. The end result being a high serum phosphorus concentration at the beginning of dialysis, a sharp decline in the value by the end of dialysis and significant rebound of serum phosphorus concentration a few hours after stopping dialysis as phosphorus moves out of the cells. Here, we describe 2 hemodialysis patients with normal predialysis serum phosphorus concentration and preexisting conditions that made them at risk for developing encephalopathy who developed recurrent obtundation toward the end of the dialysis treatments. After confirming critical postdialysis hypophosphatemia, phosphorus was added to the dialysate baths and the episodes of encephalopathy associated with dialysis ceased

Does significant renal ablation truly and invariably lead to hyperfiltration and progressive chronic kidney disease?

It is generally believed that significant renal ablation leads to hyperfiltration and eventually progressively worsening chronic kidney disease. The data behind this belief have not been scrutinized intensively. More importantly, the above belief leads many physicians to manage patients differently than they otherwise would manage. Here, we examine the data behind whether hyperfiltration occurs when patients lose kidney mass (by excision or by disease) and whether the hyperfiltration is uniformly injurious